ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Caplin Point Laboratories earnings call we streamed: the live audio and our summary of what management said.
Revenue grew 18.3% with strong H1 margins, but Q2 margins softened q/q on freight, milestone timing and line upgrades. Management is confident but deflects US margin questions to a long-term horizon.
Revenue grew 18.3% with strong H1 margins, but Q2 margins softened q/q on freight, milestone timing and line upgrades. Management is confident but deflects US margin questions to a long-term horizon.
US revenue guided 20-25% growth in FY27 despite line downtime. C OL2 completion by August 2027. CRO beds to 120 by FY-end.
Caplin reported strong Q1FY27 growth with 20% revenue and 19% PAT increase. Management is scaling capacity towards 15+ sterile lines while maintaining a debt-free balance sheet and high cash reserves.
Caplin Point delivers strong Q1FY27 growth driven by a 3x surge in US revenue. Management is aggressive on vertical integration and digitalization but faces near-term capacity constraints at key plants.
Caplin Point reported strong Q4 FY26 results with revenue doubling to INR 2,300cr and liquid assets tripling. Strategy focuses on massive injectable expansion and LATAM private market depth.
Caplin Point delivers a strong FY26 with revenue doubling over five years and a massive push into US injectables.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.